Ermaris Bio — Stock, Pipeline & Market Cap

Is this your company? Claim your profile to update info and connect with investors.

Private Company

Funding information not available

Overview

Ermaris Bio is a newly formed, pre-revenue biotech venture operating as a public benefit corporation (PBC) with a focus on extending healthspan through novel therapeutics. The company is in a strategic search and evaluation phase, leveraging its team's deep drug development expertise to identify and in-license promising early-stage assets. With a broad initial focus on oncology, immunology, ophthalmology, and cardiovascular diseases, Ermaris aims to build a pipeline by efficiently progressing selected candidates into clinical trials.

OncologyImmunologyOphthalmologyCardiovascular

Technology Platform

No proprietary platform disclosed. Core capability is expert-led search, evaluation, and development of external early-stage small molecule assets.

Opportunities

Ermaris has the opportunity to build a valuable pipeline by leveraging its team's expertise to selectively in-license high-potential, de-risked assets from academia or other sources at an early stage.

Its broad therapeutic focus allows it to pursue the most compelling science across major disease areas with significant unmet need and large market potential.

Risk Factors

The company faces extreme risk as it has no current pipeline and its entire strategy depends on successfully acquiring external assets in a competitive landscape.

It is also pre-revenue and fully reliant on raising external capital in a challenging financing environment, with no near-term prospects for profitability.

Competitive Landscape

Ermaris competes directly with numerous other biotech startups, venture capital firms, and large pharma business development teams all seeking to in-license promising early-stage assets. Its differentiation is purported to be the seasoned judgment of its team, but it lacks the dedicated therapeutic area depth or proprietary tools of many focused competitors.

More companies in Small Molecule Drugs →More companies in United States →